Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose alkylating chemotherapy in oligometastatic HRD-positive or BRCA-related breast cancer
2012-000838-19Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thiotepa, carboplatin, cyclophosphamide, doxorubicin, paclitaxel and 4 more in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival. Started May 2012; status: active.
02
Drugs
thiotepacarboplatincyclophosphamidedoxorubicinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000838-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000838-19.